leadf
logo-loader
RNS
viewErgomed PLC

Ergomed plc - Share Capital Reduction Effective

RNS Number : 6446F
Ergomed plc
18 November 2020
 

PRESS RELEASE

Share Capital Reduction Effective

Guildford, UK - 18 November 2020: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that, further to its announcements on 1 October and 19 October 2020, the High Court of England and Wales sanctioned on 10 November 2020 the Company's application for its Capital Reduction.

 

On 17 November 2020 the Registrar of Companies registered the order of the High Court confirming the Capital Reduction and the related statement of capital approved by the High Court, whereupon the Capital Reduction became effective.

 

The Company confirms that, following the Capital Reduction, the issued share capital of the Company comprises 48,717,776 ordinary shares of 1p each and there are no shares held in treasury. The total number of voting rights in the Company is therefore 48,717,776.

Terms used but not defined in this announcement are as defined in the Company's announcement of 1 October 2020.

 

ENDS

 

Enquiries:

 

Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)


Richard Barfield (Chief Financial Officer)




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Huw Jeremy (Nominated Adviser)


James Black (Broker)




Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Sue Stuart

[email protected]

Matthew Neal / Olivia Manser


 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRVDLFFBFLFFBE

Quick facts: Ergomed PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Expansion of Modus study 'great news for Ergomed Plc'

Ergomed Plc (LON:ERGO) has been cheered by news of progress in a medical study by one of its co-development partners, Modus Therapeutics. The pharma services and drug development group drew its shareholders’ attention to an announcement by Modus relating to Sevuparin, a new drug to treat...

on 11/16/2016

3 min read